You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
|
|---|---|
| Published in |
Annals of Oncology, February 2010
|
| DOI | 10.1093/annonc/mdq027 |
| Pubmed ID | |
| Authors |
F Morschhauser, P Marlton, U Vitolo, O Lindén, J F Seymour, M Crump, B Coiffier, R Foà, E Wassner, H-U Burger, B Brennan, M Mendila |
| Abstract |
Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its safety and efficacy in patients with relapsed/refractory follicular lymphoma (FL) after prior rituximab therapy. Design and methods: Forty-seven patients were treated in three dose cohorts and received eight infusions every 3 weeks: cohort A, 200 mg/m(2) (n = 15); cohort B, 375 mg/m(2) (n = 16); cohort C, first dose 375 mg/m(2), seven subsequent doses of 750 mg/m(2) (n = 16). Patients were assessed for safety, efficacy, pharmacodynamics and pharmacokinetics. |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 79 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 21% |
| Student > Ph. D. Student | 11 | 14% |
| Student > Master | 10 | 13% |
| Student > Bachelor | 8 | 10% |
| Other | 5 | 6% |
| Other | 13 | 16% |
| Unknown | 16 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 40% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Neuroscience | 5 | 6% |
| Agricultural and Biological Sciences | 5 | 6% |
| Chemistry | 5 | 6% |
| Other | 10 | 13% |
| Unknown | 17 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2010.
All research outputs
#17,285,036
of 25,371,288 outputs
Outputs from Annals of Oncology
#6,168
of 7,854 outputs
Outputs of similar age
#152,952
of 184,766 outputs
Outputs of similar age from Annals of Oncology
#42
of 47 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,854 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,766 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.